Publication at First Faculty of Medicine |
2013
Abstract
Targeted inhibitors of key cellular pathways have become the mainstay of systemic therapy for metastatic renal cell carcinoma (mRCC). Although the treatment does not have a curative potential, the prolongation of survival with good quality of life can be achieved in many patients.
Optimal treatment strategy for mRCC requires consideration of all available options and appropriate management of treatment side effects.